SISTEMA SANITARIO REGIONALE
ASL RIETI

REGIONE LAZIO

Azienda Sanitaria Locale Rieti

U.O.C. ACQUISIZIONE E LOGISTICA DI BENI E SERVIZI

DETERMINAZIONE DIRIGENZIALE

n° 446 **del** 28-02-2019

Oggetto: Affidamento diretto ai sensi dell'art. 36 c. 2 lettera a) del D.lgs. n. 50/2016 alla Società, UCS Diagnostics Srl con sede in Roma, di n. 2 Anticorpi c-My c (Y69) Mon Rabbit da 0,1 ml e n. 2 Anticorpi PAX-8 (EPR13511) Mon. Rabbit da 0,1 ml, occorrenti al UOC di Anatomia Patologica dell'Ospedale S. Camillo de Lellis di Rieti .

Importo complessivo annuo euro 3.160,00(IVA esclusa).

il Dirigente sottoscrivendo il presente provvedimento, attesta che lo stesso, a seguito dell'istruttoria effettuata, nella forma e nella sostanza, è totalmente legittimo, ai sensi dell'art. 1 della L. n. 20/1994 e ss.mm.ii., assumendone di conseguenza la relativa responsabilità, ex art. 4, comma 2, L. n. 165/2001, nonché garantendo l'osservanza dei criteri di economicità, di efficacia, di pubblicità, di imparzialità e trasparenza di cui all'art. 1, comma 1°, L. n. 241/1990, come modificato dalla L. n. 15/2005. Il dirigente attesta, altresì, che il presente provvedimento è coerente con gli obiettivi dell'Azienda ed assolutamente utile per il servizio pubblico ai sensi dell'art. 1, L. n. 20/1994 e ss.mm.ii.;

L'Estensore

Sig.ra Sabrina Brodone Firma Sabrina Brodone Data 22.02.2019

Il Direttore dell'U.O.C. ALBS

Dott. Luciano Quattrini Firma _____ Data 22-02-2019

Il Direttore della U.O.C. Economico Finanziaria con la sottoscrizione del presente atto attesta che lo stesso non comporta scostamenti *sfavorevoli* rispetto al budget economico.

Voce del conto economico su cui imputare la spesa 501010317 - AUT. 2/2019

Data 25/02/2019 Firma _____

Dott.ssa Barbara Proietti

DETERMINAZIONE DIRIGENZIALE

Visto l'art. 4, comma 2, del D.Lgs. 30 marzo 2001, n. 165 concernente le attribuzioni dei dirigenti nelle amministrazioni pubbliche;

Visto l'Atto Aziendale approvato con DCA n.113 del 18/3/2015 pubblicato sul B.U.R.L. n. 33 S.O. n.1 del 23 aprile 2015 da cui si rileva l'organizzazione aziendale ed il funzionigramma;

Vista la deliberazione n.7/D.G. del 12.12.2017 di attribuzione delle deleghe al Direttore Amministrativo, al Direttore Sanitario ed ai dirigenti delle strutture aziendali in relazione agli incarichi formalmente conferiti ed i conseguenti successivi atti di delega, integrata con delibera n.222/D.G. del 12/3/2018;

IL DIRETTORE

DELLA *U.O.C. ACQUISIZIONE E LOGISTICA DI BENI E SERVIZI*

PREMESSO che con deliberazione n. 727/DG del 09/06/2017 questa Azienda ha affidato l'acquisto di n.2 Anticorpo c-My c (Y69) Mon Rabbit da 0,1 ml e n. 2 Anticorpo PAX-8 (EPR13511) Mon. Rabbit da 0,1 ml alla Società UCS Diagnostics Srl di Roma

VISTO che è pervenuta, dalla UOC di Anatomia Patologica dell'Ospedale S. Camillo de Lellis di Rieti, ulteriore proposta d'ordine n. 2 AP/2018, comprensiva di Anticorpo PAX-8 (EPR13511) Mon. Rabbit da 0,1 ml;

RILEVATO che con mail del 18/01/2019 il Responsabile della UOC di Anatomia Patologica ha comunicato il fabbisogno annuo, degli anticorpi c-My c (Y69) Mon Rabbit da 0,1 ml e PAX-8 (EPR13511) Mon. Rabbit da 0,1 ml (All.1);

VISTO il Decreto del Presidente della Regione Lazio n. 287 del 07/07/2017 prevede di esonerare le Aziende Sanitarie dal richiedere qualsiasi autorizzazione alla Direzione Centrale Acquisti per gli acquisti di beni e servizi fino alla soglia di €uro 50.000,00 IVA esclusa;

PRECISATO che sono state invitate a produrre offerta, in merito alla fornitura degli anticorpi richiesti dal Servizio di Anatomia Patologica dell'Ospedale S. Camillo de Lellis di Rieti le società di seguito elencate:

AGILENT TECNOLOGIES SPA di MilaNO
ROCHE DIAGNOSTICS SPA di Milano
UCS DIAGNOSTICS Srl di Roma

TENUTO CONTO che, ha presentato offerta, comprensiva di schede tecniche, relative agli Anticorpo c-My c (Y69) Mon Rabbit da 0,1 ml e Anticorpo PAX-8 (EPR13511) Mon. Rabbit da 0,1 ml, solo la Società UCS Diagnostics Srl di Roma (All.2);

VISTO il parere favorevole espresso dal Responsabile della UOC di Anatomia Patologica dell'Ospedale S. Camillo de Lellis di Rieti, sulle schede tecniche dei suddetti anticorpi (All.3);

EVIDENZIATO che la Società, UCS Diagnostics Srl con sede in Roma, offre gli Anticorpi c-My c (Y69) Mon Rabbit da 0,1 ml e PAX-8 (EPR13511) Mon. Rabbit da 0,1 ml, ad € 790,00 cadauno;

CONSIDERATO che il fabbisogno annuo comunicato dalla UOC di Anatomia Patologica dell'Ospedale S. Camillo de Lellis di Rieti è di n. 2 Anticorpi c-My c (Y69) Mon Rabbit da 0,1 ml e n. 2 Anticorpi PAX-8 (EPR13511) Mon. Rabbit da 0,1 ml;

RILEVATO che il costo annuo per l'acquisto di n. 2 di Anticorpi c-My c (Y69) Mon Rabbit da 0,1 ml e n. 2 Anticorpi PAX-8 (EPR13511) Mon. Rabbit da 0,1 ml, occorrenti al UOC di Anatomia Patologica dell'Ospedale S. Camillo de Lellis di Rieti, con l'applicazione dell'IVA al 22% e complessivamente pari ad € 3.855,20;

ATTESO che gli anticorpi in argomento non sono presenti sul mercato elettronico;

CONSIDERATA l'esiguità della spesa;

RILEVATO che, è necessario procedere all'acquisto degli anticorpi in argomento per le necessità del Servizio di Anatomia Patologica dell'Ospedale S. Camillo de Lellis di Rieti nelle more della procedura di gara regionale;

DATO ATTO che la proposta è coerente con il vigente Piano Triennale Aziendale della Prevenzione della Corruzione e del Programma Triennale per la Trasparenza e l'Integrità;

D E T E R M I N A

1 Di affidare la fornitura di n. 2 Anticorpi c-My c (Y69) Mon Rabbit da 0,1 ml e n. 2 Anticorpi PAX-8 (EPR13511) Mon. Rabbit da 0,1 ml, occorrenti al UOC di Anatomia Patologica dell'Ospedale S. Camillo de Lellis di Rieti, nelle more della realizzazione della procedura di gara regionale al costo annuale di € 3.855,20 IVA compresa;

2 DI INCLUDERE l'onere del presente provvedimento complessivamente pari ad € 3.855,20IVA compresa al conto di costo 501010317 (reagenti);

3 DI DICHIARARE il presente provvedimento immediatamente esecutivo non essendo sottoposto al controllo regionale, ai sensi del combinato disposto dell'art. 30 della L.R. n. 18/94 e successive modificazioni ed integrazioni e degli artt. 21 e 22 della L.R. n. 45/96.

4 DI DISPORRE l'invio del presente atto alla U.O.C. Economico Finanziaria per i provvedimenti di competenza;

3 DI DISPORRE che il presente atto venga pubblicato nell'albo pretorio on-line aziendale ai sensi dell'art. 32, comma 1, della legge 18.09.2009, n. 69 e del D.Lgs 14.03.2013 n. 33;

in oggetto ☐ per esteso ☒

Il Direttore
U.O.C. Acquisizione e Logistica
di Beni e Servizi
(Dr. Luciano Quattrini)

VERIFICATA DAL DIRETTORE AMMINISTRATIVO O DAL DIRETTORE SANITARIO:

☑ Il Direttore Amministrativo: Dott.ssa Anna Petti

AZIENDA SANITARIA LOCALE RIETI
IL DIRETTORE AMMINISTRATIVO
(Dott.ssa Anna Petti)

☐ Il Direttore Sanitario: Dr. Vincenzo Rea_____

La presente Determinazione è inviata al Collegio Sindacale in data 28 FEB. 2019

La presente Determinazione è esecutiva ai sensi di legge 28 FEB. 2019

La presente Determinazione viene pubblicata all'albo pretorio on-line aziendale ai sensi dell'art. 32, comma 1, della legge 18.09.2009, n. 69 e del D.Lgs 14.03.2013 n. 33 in data 28 FEB. 2019

in oggetto ☐ per esteso ☒

Rieti lì 28 FEB. 2019

IL FUNZIONARIO

Da: ANNA RITA EMILI
Inviato: venerdì 18 gennaio 2019 10:57
A: Sabrina Brodone
Oggetto: anticorpi

Pag. 1 di 1

Si comunica che per quanto riguarda i seguenti prodotti il fabbisogno e di 2 confezioni ciascuno:
51765 e 51764
D'ordine Dott. Liberati

UCS DIAGNOSTIC
YOUR PARTNER FOR RESEARCH
UCS Diagnostic S.r.l. – Via Flaminia, 1 – 00067 Morlupo (RM)

Morlupo 25/01/2019 **Off. N. 25119-A**

Spett. le
Azienda USL Rieti
UOC Acquisizione e Logistica di Beni e Servizi
Via del Terminillo, 42
02100 Rieti

OGGETTO: Offerta Anticorpi c-Myc; PAX-8 (vs. richiesta Prot. N. 4010 del 24/01/2019)

Siamo lieti di sottoporre alla Vostra attenzione la nostra migliore offerta per i seguenti prodotti:

Codice	Descrizione Prodotto	Prezzo Offerta Singola Conf.
ab32072	c-Myc (Y69) Mon Rabbit 0,1 ml Conc	€ 790,00
ab189249	PAX-8 (EPR13511) Mon. Rabbit 0,1 ml Conc	€ 790,00

NO CND e Repertorio perchè entrambi i prodotti sono RUO (vedi schede tecniche allegate)

I prezzi sono al netto dell'IVA che sarà a Vostro carico nella misura di legge (22% Ventiduepercento)
Eventuali ordini andranno indirizzati a: UCS Diagnostic S.r.l Via Flaminia, 1 00067 Morlupo (RM) o per Fax allo: 06-9078292 o email: info@ucsdiagnostic.com.

Consegna Merce 10 giorni data ricevimento ordine
Porto Franco
Pagamento BB 60 gg DF
Offerta valida fino al 30/06/2019.

In attesa di un Vostro positivo riscontro, Vi inviamo distinti saluti.

UCS Diagnostic S.r.l.
Dr. Antonio Santoro
(Amministratore Unico)



abcam

Product datasheet

Anti-c-Myc antibody [Y69] ab32072

RabMAb

★★★★☆ 31 Abreviews 138 References 19 Images

Overview

Product name	Anti-c-Myc antibody [Y69]
Description	Rabbit monoclonal [Y69] to c-Myc
Specificity	This antibody is specific for endogenous c-Myc.
Tested applications	**Suitable for:** WB, ICC/IF, Flow Cyt, IHC-P, IP
Species reactivity	**Reacts with:** Mouse, Rat, Human
Immunogen	Synthetic peptide within Human c-Myc aa 1-100 (N terminal). The exact sequence is proprietary. (Peptide available as ab166837) Run BLAST with Run BLAST with
Positive control	Purchase matching WB positive control: **Recombinant human c-Myc protein** › WB: Jurkat, Raji, MCF-7, K562, THP1, A20, rat spleen, L6, Neuro-2a and Raw264.7 cell lysates. ICC/IF: HeLa cells. IHC-P: Human skin carcinoma, diffuse large B cell lymphoma, adenocarcinoma of the colon, lung adenocarcinoma, gastric adenocarcinoma, urinary bladder transitional carcinoma tissues and esophagus. IP: Jurkat cell lysate. Flow Cyt: HeLa cells.
General notes	Myc is involved in MAPK-p38 signaling pathway - see the interactive version. If you need conjugated anti-c-myc (Y69) RabMAb antibodies, find our range of products here. We also offer a PBS only version of this clone as product ab168727. Produced using Abcam's RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5, 675, 063 and/or 7, 429, 487. This product is a recombinant rabbit monoclonal antibody.

Properties

Form	Liquid
Storage instructions	Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Dissociation constant (K_D)	$K_D = 3.80 \times 10^{-12}$ M

10^{-12}

HM 2
Pag. 3 di 13

Learn more about K_D

Storage buffer	pH: 7.20 Preservative: 0.01% Sodium azide Constituents: 59% PBS, 40% Glycerol, 0.05% BSA
Purity	Protein A purified
Clonality	Monoclonal
Clone number	Y69
Isotype	IgG

Applications

Our Abpromise guarantee covers the use of **ab32072** in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
WB	☆☆☆☆☆	1/10000. Detects a band of approximately 57 kDa (predicted molecular weight: 49 kDa).Can be blocked with c-Myc peptide (ab166837).
ICC/IF	☆☆☆☆☆	Use a concentration of 10 µg/ml. 1/100.
Flow Cyt		1/76.
IHC-P		Use a concentration of 5 µg/ml. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
IP	☆☆☆☆	Use a concentration of 5 µg/ml.

Target

Function	Participates in the regulation of gene transcription. Binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Seems to activate the transcription of growth-related genes.
Involvement in disease	Note=Overexpression of MYC is implicated in the etiology of a variety of hematopoietic tumors. Note=A chromosomal aberration involving MYC may be a cause of a form of B-cell chronic lymphocytic leukemia. Translocation t(8;12)(q24;q22) with BTG1. Defects in MYC are a cause of Burkitt lymphoma (BL) [MIM:113970]. A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. Note=Chromosomal aberrations involving MYC are usually found in Burkitt lymphoma. Translocations t(8;14), t(8;22) or t(2;8) which juxtapose MYC to one of the heavy or light chain immunoglobulin gene loci.
Sequence similarities	Contains 1 basic helix-loop-helix (bHLH) domain.
Post-translational modifications	Phosphorylated by PRKDC. Phosphorylation at Thr-58 and Ser-62 by GSK3 is required for ubiquitination and degradation by the proteasome. Ubiquitinated by the SCF(FBXW7) complex when phosphorylated at Thr-58 and Ser-62, leading

to its degradation by the proteasome. In the nucleoplasm, ubiquitination is counteracted by USP28, which interacts with isoform 1 of FBXW7 (FBW7alpha), leading to its deubiquitination and preventing degradation. In the nucleolus, however, ubiquitination is not counteracted by USP28, due to the lack of interaction between isoform 4 of FBXW7 (FBW7gamma) and USP28, explaining the selective MYC degradation in the nucleolus. Also polyubiquitinated by the DCX(TRUSS) complex.

Cellular localization Nucleus > nucleoplasm. Nucleus > nucleolus.

Form c-Myc is also expressed in the cytoplasm.

Anti-c-Myc antibody [Y69] images



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-c-Myc antibody [Y69] (ab32072)

IHC image of ab32072 staining c-Myc in human esophagus formalin fixed paraffin embedded tissue sections*, performed on a Leica Bond. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab32072, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. No primary antibody was used in the Secondary only control (shown on the inset).

For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.



Immunocytochemistry/ Immunofluorescence - Anti-c-Myc antibody [Y69] (ab32072)

ab32072 staining c-Myc in HeLa cells. The cells were fixed with 4% formaldehyde (10min), permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at +4°C with ab32072 at 10µg/ml dilution (shown in green) and ab195889, mouse monoclonal to alpha Tubulin (Alexa Fluor® 594), at 2µg/ml (shown in red). Nuclear DNA was labelled with DAPI (shown in blue).

Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-c-Myc antibody [Y69] (ab32072)

Immunohistochemical analysis of paraffin-embedded Mouse spleen tissue labeling c-Myc with ab32072 at 1/500 dilution,followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution.Nuclear staining on mouse spleen.Counter stained with Hematoxylin.

Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is ab97051 at 1/500 dilution.



Immunohistochemistry (Paraffin-embedded sections) - Anti-c-Myc antibody [Y69] (ab32072)

IHC image of ab32072 staining c-Myc in human adenocarcinoma formalin fixed paraffin embedded tissue sections, performed on a Leica Bond. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab32072, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. No primary antibody was used in the negative control (shown on the inset).

For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.



Flow Cytometry - Anti-c-Myc antibody [Y69] (ab32072)

Overlay histogram showing HeLa cells stained with ab32072 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab32072, 1/76 dilution) for 30 min at 22ºC. The secondary antibody used was Alexa Fluor® 488 goat anti-rabbit IgG (H&L) preadsorbed (ab150081) at 1/2000 dilution for 30 min at 22ºC. Isotype control antibody (black line) was rabbit IgG [EPR25A] (monoclonal) (ab172730, 1µg/1x10^6 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control.

Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 nm bandpass filter.



Immunocytochemistry/ Immunofluorescence - Anti-c-Myc antibody [Y69] (ab32072)

Immunocytochemistry/immunofluorescence analysis of HeLa cells labelling c-Myc with purified ab32072 at 1/100. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, an Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/500) was used as the secondary antibody. DAPI (blue) was used as the nuclear counterstain.

Control: primary antibody (1/100) and secondary antibody, ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/500).



Immunocytochemistry/ Immunofluorescence - Anti-c-Myc antibody [Y69] (ab32072)

Image courtesy of Dr Vladimir Milenkovic by Abreview.

Unpurified ab32072 staining c-Myc in HEK293 cells transfected with CACNB4-c-Myc by immunocytochemistry/ immunofluorescence.Cells were fixed in paraformaldehyde, permeabilized with 0.5% Triton X-100 then blocked using 5% serum for 20 minutes at 25°C. Samples were then incubated with ab32072 at a 1/250 dilution for 16 hours at 4°C. The secondary used was an Alexa Fluor® 488 conjugated goat anti-rabbit polyclonal, used at a 1/500 dilution.



Immunocytochemistry/ Immunofluorescence - Anti-c-Myc antibody [Y69] (ab32072)

ICC/IF image of unpurified ab32072 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab32072, 1µg/ml) overnight at +4°C. The secondary antibody (green) was anti rabbit DyLight® 488 IgG - H&L, pre-adsorbed (ab96899) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.



Western blot - Anti-c-Myc antibody [Y69] (ab32072)

All lanes : Anti-c-Myc antibody [Y69] (ab32072) at 1/1000 dilution

Lane 1 : MCF-7 (Human breast adenocarcinoma epithelial cell) whole cell lysates
Lane 2 : Raji (Human Burkitt's lymphoma B lymphocyte) whole cell lysates
Lane 3 : K562 (Human chronic myelogenous leukemia lymphoblast) whole cell lysates
Lane 4 : Jurkat (Human T cell leukemia T lymphocyte) whole cell lysates
Lane 5 : THP-1 (Human monocytic leukemia monocyte) whole cell lysates
Lane 6 : Rat spleen whole cell lysates
Lane 7 : L6 (Rat skeletal muscle myoblast) whole cell lysates
Lane 8 : Neuro-2a (Mouse neuroblastoma neuroblast) whole cell lysates
Lane 9 : RAW264.7 (Mouse Abelson murine leukemia virus-induced tumor macrophage) whole cell lysates

Lysates/proteins at 20 µg per lane.

Secondary
Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/20000 dilution

Predicted band size : 49 kDa
Observed band size : 57 kDa

Exposure time : 3 minutes
Blocking and dilution buffer: 5% NFDM/TBST.



Western blot - Anti-c-Myc antibody [Y69] (ab32072)

All lanes : Anti-c-Myc antibody [Y69] (ab32072) at 1/1000 dilution (unpurified)

Lane 1 : Raji (Human Burkitt's lymphoma cell line) Whole Cell Lysate
Lane 2 : K562 (Human erythromyeloblastoid leukemia cell line) Whole Cell Lysate
Lane 3 : THP1 (Human acute monocytic leukemia cell line) Whole Cell Lysate
Lane 4 : A20 (Mouse B lymphoma cell line) Whole Cell Lysate
Lane 5 : RAW 264.7 (Mouse leukaemic monocyte macrophage cell line) Whole Cell Lysate

Lysates/proteins at 20 µg per lane.

Secondary
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/50000 dilution
Developed using the ECL technique

Performed under reducing conditions.

Predicted band size : 49 kDa
Observed band size : 57 kDa
The predicted molecular weight of c-Myc is 48 kDa (SwissProt), however we expect to observe a banding pattern at 57 kDa.

This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab32072 overnight at 4°C. Antibody binding was detected using an anti-rabbit HRP antibody, and visualised using ECL development solution ab133406.



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-c-Myc antibody [Y69] (ab32072)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human diffuse large B cell lymphoma tissue labelling c-Myc with purified ab32072 at 1/500. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. ab97051, a HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/500). Negative control using PBS instead of primary antibody. Counterstained with hematoxylin.



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-c-Myc antibody [Y69] (ab32072)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human adenocarcinoma of the colon tissue labelling c-Myc with purified ab32072 at 1/500. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. ab97051, a HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/500). Negative control using PBS instead of primary antibody. Counterstained with hematoxylin.



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-c-Myc antibody [Y69] (ab32072)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human skin carcinoma tissue labelling c-Myc with unpurified ab32072 at 1/50.



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-c-Myc antibody [Y69] (ab32072)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human adenocarinoma of colon tissue labelling c-Myc with unpurified ab32072.



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-c-Myc antibody [Y69] (ab32072)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human lung adenocarinoma tissue labelling c-Myc with unpurified ab32072.



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-c-Myc antibody [Y69] (ab32072)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human gastric adenocarcinoma tissue labelling c-Myc with unpurified ab32072.



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-c-Myc antibody [Y69] (ab32072)

Immunohistochemistry (Formalin/PFA-fixed parffin-embedded sections) analysis of human urinary bladder transitional carcinoma tissue labelling c-Myc with unpurified ab32072.



Immunoprecipitation - Anti-c-Myc antibody [Y69] (ab32072)

c-Myc was immunoprecipitated using 0.5mg Jurkat whole cell extract, 5µg of unpurified rabbit monoclonal to c-Myc [Y69] and 50µl of protein G magnetic beads (+). No antibody was added to the control (-).

The antibody was incubated under agitation with Protein G beads for 10min, Jurkat whole cell extract lysate diluted in RIPA buffer was added to each sample and incubated for a further 10min under agitation.

Proteins were eluted by addition of 40µl SDS loading buffer and incubated for 10min at 70°C; 10µl of each sample was separated on a SDS PAGE gel, transferred to a nitrocellulose membrane, blocked with 5% BSA and probed with unpurified ab32072.

Secondary: Goat polyclonal to mouse IgG light chain specific (HRP) at 1/20,000 dilution.

Band: 57kDa; c-Myc [Y69]



Other - Anti-c-Myc antibody [Y69] (ab32072)

Equilibrium disassociation constant (K_D)

Learn more about K_D

Click here to learn more about K_D

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours

- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit http://www.abcam.com/abpromise or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors

abcam

Product datasheet

Anti-PAX8 antibody [EPR13511] - C-terminal ab189249

RabMAb

☆☆☆☆ 1 Abreviews 1 References 4 Images

Overview

Product name	Anti-PAX8 antibody [EPR13511] - C-terminal
Description	Rabbit monoclonal [EPR13511] to PAX8 - C-terminal
Tested applications	**Suitable for:** IHC-P, ICC/IF, Flow Cyt
Species reactivity	**Reacts with:** Human **Predicted to work with:** Mouse, Rat, Dog, Orangutan ⚠
Immunogen	Recombinant full length protein aa 300 to the C-terminus (C terminal). The exact sequence is proprietary. Database link: Q06710 Run BLAST with Run BLAST with
Positive control	Human thyroid carcinoma tissue. HeLa cells.
General notes	Produced using Abcam's RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5, 675, 063 and/or 7, 429, 487. **We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.** This product is a recombinant rabbit monoclonal antibody.

Properties

Form	Liquid
Storage instructions	Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage buffer	Preservative: 0.01% Sodium azide Constituents: 59% PBS, 40% Glycerol, 0.05% BSA
Purity	Protein A purified
Clonality	Monoclonal
Clone number	EPR13511
Isotype	IgG

Our Abpromise guarantee covers the use of **ab189249** in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
IHC-P		1/200 - 1/500. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
ICC/IF	☆☆☆☆☆	1/250 - 1/500.
Flow Cyt		Use at an assay dependent concentration.

Target

Function	Transcription factor for the thyroid-specific expression of the genes exclusively expressed in the thyroid cell type, maintaining the functional differentiation of such cells.
Tissue specificity	Expressed in the excretory system, thyroid gland and Wilms tumors.
Involvement in disease	Defects in PAX8 are the cause of congenital hypothyroidism non-goitrous type 2 (CHNG2) [MIM:218700]. CHNG2 is a disease characterized by thyroid dysgenesis, the most frequent cause of congenital hypothyroidism, accounting for 85% of case. The thyroid gland can be completely absent (athyreosis), ectopically located and/or severely hypoplastic. Ectopic thyroid gland is the most frequent malformation, with thyroid tissue being found most often at the base of the tongue.
Sequence similarities	Contains 1 paired domain.
Developmental stage	In developing excretory system, during thyroid differentiation and in adult thyroid.
Cellular localization	Nucleus.

Anti-PAX8 antibody [EPR13511] - C-terminal images



Flow Cytometry - Anti-PAX8 antibody [EPR13511] - C-terminal (ab189249)

ab189249 staining PAX8 in the human cell line MCF-7(human breast carcinoma) by flow cytometry. Cells were fixed with 4% paraformaldehyde, permeabilized with 90% methanol and the sample was incubated with the primary antibody at a dilution of 1/20. A goat anti rabbit IgG (Alexa Fluor® 488) at a dilution of 1/2000 was used as the secondary antibody.

Isoytype control: Rabbit monoclonal IgG (Black)

Unlabelled control: Cell without incubation with primary antibody and secondary antibody (Blue)



Immunocytochemistry/ Immunofluorescence - Anti-PAX8 antibody [EPR13511] - C-terminal (ab189249)

Immunocytochemistry/Immunofluorescence analysis of MCF-7 (human breast carcinoma) labelling PAX8 with purified ab189249 at 1/500. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. An Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody (Ab150077). Nuclei counterstained with DAPI (blue).

Control: PBS only



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - (ab189249)

Immunohistochemical analysis of formalin fixed paraffin embedded human thyroid carcinoma labeling PAX8 with ab189249 at a 1/500 dilution and HRP Polymer for Rabbit IgG. Counterstained with Hematoxylin.



Immunocytochemistry/ Immunofluorescence - (ab189249)

Immunocytochemical analysis of HeLa cells fixed in 4% paraformaldehyde labeling PAX8 with ab189249 at 1/250 dilution and Goat anti rabbit IgG(Alexa Fluor® 555) at 1/200 dilution. Counterstained with DAPI (right).

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors

Pag. 18 di 19

All. 3
Pag. 1 di 1

Re: Approvvigionamento anticorpo Pax8

FABRIZIO LIBERATI
mer 20/02/2019 13:30
A: Sabrina Brodone <s.brodone@asl.rieti.it>

Buongiorno sig.ra Brodone,
dopo avere verificato la correttezza delle schede tecniche esprimo parere favorevole all'acquisto dei due prodotti per immunoistochimica.
Cordiali saluti
Dott. Fabrizio Liberati

Da: Sabrina Brodone
Inviato: mercoledì 20 febbraio 2019 13:02:04
A: FABRIZIO LIBERATI; ANNA RITA EMILI
Oggetto: I: Approvvigionamento anticorpo Pax8

Buongiorno, resto in attesa di parere in merito.
Cordiali saluti.

Sabrina Brodone
UOC Acquisizione e Logistica di Beni e Servizi
Azienda USL Rieti
Tel. 0746-279569
Fax. 0746-278730